<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753853</url>
  </required_header>
  <id_info>
    <org_study_id>Lipo-Tend</org_study_id>
    <nct_id>NCT04753853</nct_id>
  </id_info>
  <brief_title>Stromal Vascular Fraction (SVF) Injection in the Treatment of Patellar Tendinopathy</brief_title>
  <official_title>Effect of Infiltrative Treatment of Stromal Vascular Fraction in Patellar Tendinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the evaluation of clinical and radiological results after the&#xD;
      treatment of patellar tendinopathy through the injection of autologous ultrasound-guided,&#xD;
      intra- and peri-tendon stromal vascular fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will be treated according to the study protocol.&#xD;
&#xD;
      Every patients will undergo to a single peri- and intra- tendon injection with Autologous&#xD;
      Stromal Vascula Fraction (SVF).&#xD;
&#xD;
      At baseline and at every follow-ups patients will be evaluated clinically and radiologically.&#xD;
&#xD;
      In particular, clinical evaluation and questionnaires will be performed at baseline, 1, 3, 6,&#xD;
      12 and 24 months visits, Ultrasound will be performed at baseline, 6 and 12 months visits.&#xD;
      MRI will be performed at baseline and 6 months visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional Pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>VISA-P score is a questionnaire that assesses symptoms, simple tests of function, and the ability to play sports. It contains 8 questions about patellar tendinosis, max score for asymptomatic individual is 100; theoretical minimum is 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Victorian Institute of Sport Assessment-Patella (VISA-P) questionnaire</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months (at 24 month the questionnaire will be performed by telephone)</time_frame>
    <description>VISA-P score is a questionnaire that assesses symptoms, simple tests of function, and the ability to play sports. It contains 8 questions about patellar tendinosis, max score for asymptomatic individual is 100; theoretical minimum is 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Visual Analogue Scale (EQ-VAS)</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months (at 24 month the questionnaire will be performed by telephone)</time_frame>
    <description>EQ-VAS, which asks patients to indicate their overall health on a vertical visual analogue scale, ranging from &quot;worst possible&quot; to &quot;best possible&quot; health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D(EuroQol)</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months (at 24 month the questionnaire will be performed by telephone)</time_frame>
    <description>the EQ-5D profile, asks patients to classify their health based on self-assessed levels of problems (&quot;no&quot;, &quot;some&quot;, &quot;extreme&quot;) on five dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale - VAS</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months (at 24 month the questionnaire will be performed by telephone)</time_frame>
    <description>Analogue scale represented by a line of 10 cm length, ranging from &quot;absence of pain&quot; to &quot;the worst imaginable pain &quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner score</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months (at 24 month the questionnaire will be performed by telephone)</time_frame>
    <description>Tegner's activity scale classifies the activity according to work and sports activities on a scale from 0 to 10. Zero represents disability because of knee problems and 10 represents soccer a national or international level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI evaluation</measure>
    <time_frame>baseline and 6 month</time_frame>
    <description>MRI performing and evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ultrasound</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>ultrasound performing and thickness evaluation of the tendon</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patellar Tendinitis</condition>
  <condition>Tendinopathy</condition>
  <condition>Patellar Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Stromal Vascular Fraction injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stromal Vascular Fraction injection</intervention_name>
    <description>intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction</description>
    <arm_group_label>Stromal Vascular Fraction injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ultrasound or MRI signs of patellar tendon pathology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Patients suffering from: rheumatic diseases, diabetes, infectious processes, epilepsy,&#xD;
             severe osteoporosis&#xD;
&#xD;
          -  Patients undergoing intra-tendon infiltration of another substance within the previous&#xD;
             6 months;&#xD;
&#xD;
          -  Patients who had patellar tendon surgery within the previous 12 months;&#xD;
&#xD;
          -  Immunodepression&#xD;
&#xD;
          -  On going systemic inflammatory diseases (stabilized outcomes of such diseases are not&#xD;
             considered absolute contraindications).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Daniele Andreani, M.Sc.</last_name>
    <phone>0516366072</phone>
    <email>daniele.andreani@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefano Zaffagnini, MD, Prof</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Di Martino, MD</last_name>
      <phone>6366567</phone>
      <phone_ext>051</phone_ext>
      <email>alessandro.dimartino@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Licciardi, MSc</last_name>
      <phone>6366567</phone>
      <phone_ext>051</phone_ext>
      <email>roberta.licciardi@ior.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stromal vascular fraction</keyword>
  <keyword>patellar tendinopathy</keyword>
  <keyword>injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

